Guggenheim Securities Initiates Coverage on BOSTON SCIENTIFIC CORP COM to Buy

Guggenheim Securities Initiates Coverage on BOSTON SCIENTIFIC CORP COM(NYSE:BSX). The shares have been rated Buy. The rating by Guggenheim Securities was issued on Jun 9, 2016.

In a different note, On May 23, 2016, BTIG Research said it Downgrades its rating on BOSTON SCIENTIFIC CORP COM. The shares have been rated ‘Neutral’ by the firm. Nomura said it Initiates Coverage on BOSTON SCIENTIFIC CORP COM, according to a research note issued on Mar 17, 2016. The shares have been rated ‘Buy’ by the firm.

BOSTON SCIENTIFIC CORP COM (BSX) shares turned negative on Wednesdays trading session with the shares closing down -0.13 points or -0.57% at a volume of 64,50,821. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $23.035. The peak price level was also seen at $23.035 while the days lowest was $22.75. Finally the shares closed at $22.8. The 52-week high of the shares is $23.35 while the 52-week low is $14.1801. According to the latest information available, the market cap of the company is $30,937 M.

BOSTON SCIENTIFIC CORP COM(BSX) last announced its earnings results on Apr 27, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $1.96B. Analysts had an estimated revenue of $1.91B. Earnings per share were $0.28. Analysts had estimated an EPS of $0.24.

Several Insider Transactions has been reported to the SEC. On Jun 3, 2016, Timothy A. Pratt (EVP, GC & Chief Admin Officer) sold 24,229 shares at $22.66 per share price.Also, On Jun 3, 2016, Michael F Mahoney (President & CEO) sold 100,000 shares at $22.69 per share price.On May 12, 2016, Keith D Dawkins (EVP, Global Chief Med. Off.) sold 80,000 shares at $22.15 per share price, according to the Form-4 filing with the securities and exchange commission.

Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Women’s Health and Neuromodulation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *


Top Brokerage Firms are advising their investors on BOSTON SCIENTIFIC CORP COM. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.